$MACK News Merrimack Pharma shares surge on li
Post# of 102911
Posted On: 11/08/2014 10:59:50 AM
$MACK News
Merrimack Pharma shares surge on licensing pact with Baxter 6:54 a.m. Sept. 24, 2014 - Tomi Kilgore
Stock futures rise on Bernanke rate comments 4:46 p.m. July 10, 2013 - Wallace Witkowski
Merrimack to offer $50 mln in stock, $75 mln notes 4:24 p.m. July 10, 2013 - MarketWatch.com
Stocks to watch Friday: Goldman, Bally, Scotts 5:54 a.m. Aug. 10, 2012 - MarketWatch
IPO scorecard: Update on selected offering 1:18 p.m. June 8, 2012 - Dow Jones
Shares of Merrimack Pharmaceuticals off post IPO 2:19 a.m. March 30, 2012 - MarketWatch.com
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog 4:35 p.m. Nov. 7, 2014 - Zacks.com
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog 4:30 p.m. Nov. 7, 2014 - Zacks.com
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog 4:02 p.m. Nov. 6, 2014 - Zacks.com
What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog 3:40 p.m. Nov. 5, 2014 - Zacks.com
Merrimack cancer candidate tagged an Orphan Drug 11:26 a.m. Nov. 5, 2014 - Seeking Alpha
Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? - Tale of the Tape 8:36 a.m. Nov. 5, 2014 - Zacks.com
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog 3:50 p.m. Nov. 4, 2014 - Zacks.com
Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape 9:39 a.m. Nov. 3, 2014 - Zacks.com
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape 8:51 a.m. Nov. 3, 2014 - Zacks.com
Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% - Tale of the Tape 8:44 a.m. Nov. 3, 2014 - Zacks.com
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape 9:39 a.m. Oct. 31, 2014 - Zacks.com
Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% - Tale of the Tape 8:51 a.m. Oct. 31, 2014 - Zacks.com
Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape 9:39 a.m. Oct. 30, 2014 - Zacks.com
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape 8:51 a.m. Oct. 30, 2014 - Zacks.com
Baxter Deal Justifies The Potential Of Merrimack's MM-398 12:35 p.m. Oct. 27, 2014 - Seeking Alpha
Verastem (VSTM) Shows Strength: Stock Adds 7% in Session - Tale of the Tape 9:39 a.m. Oct. 27, 2014 - Zacks.com
Merrimack Pharmaceuticals (MACK) Shares March Higher, Can It Continue? - Tale of the Tape 9:07 a.m. Oct. 27, 2014 - Zacks.com
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape 8:51 a.m. Oct. 27, 2014 - Zacks.com
Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case - Analyst Blog 4:39 p.m. Oct. 24, 2014 - Zacks.com
ZIOPHARM Oncology (ZIOP) Jumps: Stock Moves Up 8.5% - Tale of the Tape 8:51 a.m. Oct. 24, 2014 - Zacks.com
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer 8:31 a.m. Nov. 6, 2014 - GlobeNewswire
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer 9:01 a.m. Nov. 5, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call 8:01 a.m. Nov. 3, 2014 - GlobeNewswire
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 7:45 a.m. Oct. 22, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer 7:00 a.m. Sept. 30, 2014 - GlobeNewswire
PharmaEngine and Merrimack Amend MM-398 License Agreement 3:58 a.m. Sept. 26, 2014 - BusinessWire - BZX
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 6:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress 7:00 a.m. Sept. 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval 6:06 a.m. Aug. 11, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results 6:01 a.m. Aug. 11, 2014 - GlobeNewswire
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax 7:50 a.m. Aug. 7, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call 3:02 p.m. Aug. 4, 2014 - GlobeNewswire
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 5:40 a.m. June 27, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 3:05 p.m. June 25, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 7:15 a.m. June 25, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121 3:15 p.m. June 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 7:01 a.m. June 17, 2014 - GlobeNewswire
Battle of the Biotech Bands - A Great Time for a Great Cause 1:45 p.m. June 12, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting 3:00 p.m. June 2, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers 8:36 a.m. June 2, 2014 - GlobeNewswire
Merrimack Pharma shares surge on licensing pact with Baxter 6:54 a.m. Sept. 24, 2014 - Tomi Kilgore
Stock futures rise on Bernanke rate comments 4:46 p.m. July 10, 2013 - Wallace Witkowski
Merrimack to offer $50 mln in stock, $75 mln notes 4:24 p.m. July 10, 2013 - MarketWatch.com
Stocks to watch Friday: Goldman, Bally, Scotts 5:54 a.m. Aug. 10, 2012 - MarketWatch
IPO scorecard: Update on selected offering 1:18 p.m. June 8, 2012 - Dow Jones
Shares of Merrimack Pharmaceuticals off post IPO 2:19 a.m. March 30, 2012 - MarketWatch.com
Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog 4:35 p.m. Nov. 7, 2014 - Zacks.com
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog 4:30 p.m. Nov. 7, 2014 - Zacks.com
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog 4:02 p.m. Nov. 6, 2014 - Zacks.com
What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog 3:40 p.m. Nov. 5, 2014 - Zacks.com
Merrimack cancer candidate tagged an Orphan Drug 11:26 a.m. Nov. 5, 2014 - Seeking Alpha
Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? - Tale of the Tape 8:36 a.m. Nov. 5, 2014 - Zacks.com
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog 3:50 p.m. Nov. 4, 2014 - Zacks.com
Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape 9:39 a.m. Nov. 3, 2014 - Zacks.com
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape 8:51 a.m. Nov. 3, 2014 - Zacks.com
Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% - Tale of the Tape 8:44 a.m. Nov. 3, 2014 - Zacks.com
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape 9:39 a.m. Oct. 31, 2014 - Zacks.com
Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% - Tale of the Tape 8:51 a.m. Oct. 31, 2014 - Zacks.com
Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape 9:39 a.m. Oct. 30, 2014 - Zacks.com
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape 8:51 a.m. Oct. 30, 2014 - Zacks.com
Baxter Deal Justifies The Potential Of Merrimack's MM-398 12:35 p.m. Oct. 27, 2014 - Seeking Alpha
Verastem (VSTM) Shows Strength: Stock Adds 7% in Session - Tale of the Tape 9:39 a.m. Oct. 27, 2014 - Zacks.com
Merrimack Pharmaceuticals (MACK) Shares March Higher, Can It Continue? - Tale of the Tape 9:07 a.m. Oct. 27, 2014 - Zacks.com
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape 8:51 a.m. Oct. 27, 2014 - Zacks.com
Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case - Analyst Blog 4:39 p.m. Oct. 24, 2014 - Zacks.com
ZIOPHARM Oncology (ZIOP) Jumps: Stock Moves Up 8.5% - Tale of the Tape 8:51 a.m. Oct. 24, 2014 - Zacks.com
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer 8:31 a.m. Nov. 6, 2014 - GlobeNewswire
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer 9:01 a.m. Nov. 5, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call 8:01 a.m. Nov. 3, 2014 - GlobeNewswire
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 7:45 a.m. Oct. 22, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer 7:00 a.m. Sept. 30, 2014 - GlobeNewswire
PharmaEngine and Merrimack Amend MM-398 License Agreement 3:58 a.m. Sept. 26, 2014 - BusinessWire - BZX
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 6:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress 7:00 a.m. Sept. 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval 6:06 a.m. Aug. 11, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results 6:01 a.m. Aug. 11, 2014 - GlobeNewswire
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax 7:50 a.m. Aug. 7, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call 3:02 p.m. Aug. 4, 2014 - GlobeNewswire
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 5:40 a.m. June 27, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 3:05 p.m. June 25, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 7:15 a.m. June 25, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121 3:15 p.m. June 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 7:01 a.m. June 17, 2014 - GlobeNewswire
Battle of the Biotech Bands - A Great Time for a Great Cause 1:45 p.m. June 12, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting 3:00 p.m. June 2, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers 8:36 a.m. June 2, 2014 - GlobeNewswire
(0)
(0)